These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 17351558)

  • 21. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension.
    Tzimos A; Samokhvalov V; Kramer M; Ford L; Gassmann-Mayer C; Lim P; Eerdekens M
    Am J Geriatr Psychiatry; 2008 Jan; 16(1):31-43. PubMed ID: 18165460
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Remission of drug-induced hepatitis after switching from risperidone to paliperidone.
    Paulzen M; Orfanos S; Gründer G
    Am J Psychiatry; 2010 Mar; 167(3):351-2. PubMed ID: 20194492
    [No Abstract]   [Full Text] [Related]  

  • 23. Hospitalization rates before and after initiation of paliperidone ER in patients with schizophrenia: results from open-label extensions of the US double-blind trials.
    Janicak PG; Wu JH; Mao L
    Curr Med Res Opin; 2008 Jun; 24(6):1807-15. PubMed ID: 18559166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Obsessive-compulsive symptoms induced by long-acting injectable paliperidone in a patient with schizophrenia: a case report.
    Vázquez-Bourgon J; Rodríguez-Rodríguez P; Gómez-Ruíz E; Artal J; Crespo-Facorro B
    Ann Clin Psychiatry; 2014 Nov; 26(4):301-2. PubMed ID: 25401718
    [No Abstract]   [Full Text] [Related]  

  • 25. [Pharmacological properties of paliperidone ER (INVEGA(®)) and results of its clinical studies].
    Nagino K; Koh T; Harada Y
    Nihon Yakurigaku Zasshi; 2011 Jun; 137(6):245-54. PubMed ID: 21666344
    [No Abstract]   [Full Text] [Related]  

  • 26. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study.
    Marder SR; Kramer M; Ford L; Eerdekens E; Lim P; Eerdekens M; Lowy A
    Biol Psychiatry; 2007 Dec; 62(12):1363-70. PubMed ID: 17601495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paliperidone use in the elderly.
    Madhusoodanan S; Zaveri D
    Curr Drug Saf; 2010 Apr; 5(2):149-52. PubMed ID: 20406162
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Iloperidone for schizophrenia.
    Rado J; Janicak PG
    Expert Opin Pharmacother; 2010 Aug; 11(12):2087-93. PubMed ID: 20586713
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single- and multiple-dose pharmacokinetics and dose proportionality of the psychotropic agent paliperidone extended release.
    Boom S; Talluri K; Janssens L; Remmerie B; De Meulder M; Rossenu S; van Osselaer N; Eerdekens M; Cleton A
    J Clin Pharmacol; 2009 Nov; 49(11):1318-30. PubMed ID: 19713555
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Paliperidone extended-release: a review of efficacy and tolerability in schizophrenia, schizoaffective disorder and bipolar mania.
    Canuso CM; Battisti WP
    Expert Opin Pharmacother; 2010 Oct; 11(15):2557-67. PubMed ID: 20854185
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Paliperidone].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 2006 Aug; 29(8):280-2. PubMed ID: 16927595
    [No Abstract]   [Full Text] [Related]  

  • 32. Practical guidelines on the use of paliperidone palmitate in schizophrenia.
    Newton R; Hustig H; Lakshmana R; Lee J; Motamarri B; Norrie P; Parker R; Schreiner A
    Curr Med Res Opin; 2012 Apr; 28(4):559-67. PubMed ID: 22321007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Paliperidone--a novel second-generation antipsychotic].
    Maknyte K; Lublin HK
    Ugeskr Laeger; 2008 Aug; 170(35):2679-81. PubMed ID: 18761856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment with paliperidone extended-release tablets in a case of resistant undifferentiated schizophrenia: clinical improvement with 12 mg and evaluation through 3TRE scale].
    Rusconi AC; Carlone C; Muscillo M; Piccione M
    Riv Psichiatr; 2009; 44(4):267-72. PubMed ID: 20066799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Iloperidone for the management of adults with schizophrenia.
    Crabtree BL; Montgomery J
    Clin Ther; 2011 Mar; 33(3):330-45. PubMed ID: 21600386
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Efficacy, tolerability and safety of paliperidone extended-release in the treatment of schizophrenia and schizoaffective disorder].
    Bellantuono C; Santone G
    Riv Psichiatr; 2012; 47(1):5-20. PubMed ID: 22358213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies.
    Emsley R; Berwaerts J; Eerdekens M; Kramer M; Lane R; Lim P; Hough D; Palumbo J
    Int Clin Psychopharmacol; 2008 Nov; 23(6):343-56. PubMed ID: 18854723
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Non-fatal paliperidone overdose: a case report].
    Gill JS; Pillai SK; Koh OH; Jambunathan S
    Turk Psikiyatri Derg; 2010; 21(4):331-4. PubMed ID: 21125508
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paliperidone for treatment of obsessive compulsive resistant symptoms in schizophrenia: a case report.
    Angelucci F; Ricci V; Martinotti G; Caltagirone C; Bria P
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Oct; 33(7):1277-8. PubMed ID: 19555731
    [No Abstract]   [Full Text] [Related]  

  • 40. Manic symptoms induced by paliperidone.
    Hsieh CH; Liou YJ
    J Clin Psychopharmacol; 2010 Apr; 30(2):202-4. PubMed ID: 20520298
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.